Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The emergence and spread of multidrug-resistant gram-positive bacteria represent a serious clinical problem. Telavancin is a novel lipoglycopeptide antibiotic that possesses rapid in vitro bactericidal activity against a broad spectrum of clinically relevant gram-positive pathogens. Here we demonstrate that telavancin's antibacterial activity derives from at least two mechanisms. As observed with vancomycin, telavancin inhibited late-stage peptidoglycan biosynthesis in a substrate-dependent fashion and bound the cell wall, as it did the lipid II surrogate tripeptide N , N ′-diacetyl- l -lysinyl- d -alanyl- d -alanine, with high affinity. Telavancin also perturbed bacterial cell membrane potential and permeability. In methicillin-resistant Staphylococcus aureus , telavancin caused rapid, concentration-dependent depolarization of the plasma membrane, increases in permeability, and leakage of cellular ATP and K + . The timing of these changes correlated with rapid , concentration-dependent loss of bacterial viability, suggesting that the early bactericidal activity of telavancin results from dissipation of cell membrane potential and an increase in membrane permeability. Binding and cell fractionation studies provided direct evidence for an interaction of telavancin with the bacterial cell membrane; stronger binding interactions were observed with the bacterial cell wall and cell membrane relative to vancomycin. We suggest that this multifunctional mechanism of action confers advantageous antibacterial properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Wikler, M. A., & Clinical (2006) · Clinical and Laboratory Standards Institute eBooks · Cited by 2,843
Use of the Cell Wall Precursor Lipid II by a Pore-Forming Peptide Antibiotic
Breukink, E., Wiedemann, I., Kraaij, C. V., Kuipers, O. P., Sahl, H.-G., & de Kruijff, B. (1999) · Science · doi:10.1126/science.286.5448.2361 · Cited by 814
Wu, M., Maier, E., Benz, R., & Hancock, R. E. W. (1999) · Biochemistry · doi:10.1021/bi9826299 · Cited by 736
Structure, biochemistry and mechanism of action of glycopeptide antibiotics
Reynolds, P. E. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01967563 · Cited by 699 · cited 2×
“This multifunctional activity may provide advantages to telavancin that are absent in antibacterials such as vancomycin that possess only a single antibacterial mechanism (46, 53).”
BackgroundCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656
Staphylococcus aureus resistant to vancomycin--United States, 2002.
(2002) · PubMed · Cited by 569
THE STRUCTURE AND MODE OF ACTION OF GLYCOPEPTIDE ANTIBIOTICS OF THE VANCOMYCIN GROUP
Barna, J. C. J., & Williams, D. H. (1984) · Annual Review of Microbiology · doi:10.1146/annurev.mi.38.100184.002011 · Cited by 528
Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story
Walsh, C. T., Fisher, S. L., Park, I.-S., Prahalad, M., & Wu, Z. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90079-4 · Cited by 387
Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding d -Ala- d -Ala
Ge, M., Chen, Z., Russell, H., Onishi, Kohler, J., Silver, L. L., Kerns, R., Fukuzawa, S., Thompson, C., & Kahne, D. (1999) · Science · doi:10.1126/science.284.5413.507 · Cited by 318
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297
Mechanism of action of oritavancin and related glycopeptide antibiotics
Allen, N. (2003) · FEMS Microbiology Reviews · doi:10.1016/s0168-6445(02)00144-4 · Cited by 276
Sampson, B. A., Misra, R., & Benson, S. A. (1989) · Genetics · doi:10.1093/genetics/122.3.491 · Cited by 263
Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics
Beauregard, D. A., Williams, D. H., Gwynn, M. N., & Knowles, D. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.781 · Cited by 244
Jørgensen, T. J. D., Roepstorff, P., & Heck, A. J. R. (1998) · Analytical Chemistry · doi:10.1021/ac980563h · Cited by 202
Yeaman, M. R., Bayer, A. S., Koo, S. P., Foss, W., & Sullam, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci562 · Cited by 189
Colton, I. J., Carbeck, J. D., Rao, J., & Whitesides, G. M. (1998) · ELECTROPHORESIS · doi:10.1002/elps.1150190303 · Cited by 189
Reductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity.
COOPER, R. D. G., SNYDER, N. J., ZWEIFEL, M. J., STASZAK, M. A., WILKIE, S. C., NICAS, T. I., MULLEN, D. L., BUTLER, T. F., RODRIGUEZ, M. J., HUFF, B. E., et al. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.575 · Cited by 181
Brumfitt, W. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf190 · Cited by 166
Hydrophobic Vancomycin Derivatives with Improved ADME Properties: Discovery of Telavancin (TD-6424)
LEADBETTER, M. R., ADAMS, S. M., BAZZINI, B., FATHEREE, P. R., KARR, D. E., KRAUSE, K. M., LAM, B. M. T., LINSELL, M. S., NODWELL, M. B., PACE, J. L., et al. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.326 · Cited by 165
Self-citationChen, L., Walker, D., Sun, B., Hu, Y., Walker, S., & Kahne, D. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931492100 · Cited by 145
Structural modifications of glycopeptide antibiotics
Malabarba, A., Nicas, T. I., & Thompson, R. C. (1997) · Medicinal Research Reviews · Cited by 140
Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria
Hegde, S. S., Reyes, N., Wiens, T., Vanasse, N., Skinner, R., McCullough, J. L., Kaniga, K., Pace, J., Thomas, R., Shaw, J., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.3043-3050.2004 · Cited by 135
Self-citationFluorescent Method for Monitoring Cheese Starter Permeabilization and Lysis
Bunthof, C. J., van Schalkwijk, S., Meijer, W., Abee, T., & Hugenholtz, J. (2001) · Applied and Environmental Microbiology · doi:10.1128/aem.67.9.4264-4271.2001 · Cited by 123
Nicas, T. I., MULLEN, D. L., Flokowitsch, J. E., Preston, D. A., SNYDER, N. J., Zweifel, M. J., Wilkie, S. C., Rodriguez, M. J., Thompson, R. C., & Cooper, R. D. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.2194 · Cited by 114
King, A., Phillips, I., & Kaniga, K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh156 · Cited by 114
Self-citationIn Vitro Activity of TD-6424 againstStaphylococcus aureus
Pace, J., Krause, K. M., Johnston, D., Debabov, D. V., Wu, T. X., Farrington, L., Lane, C. M., Higgins, D. L., Christensen, B., Judice, J. K., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3602-3604.2003 · Cited by 109
Self-citationGoldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., & Fernandez, H. T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2149-2152.2004 · Cited by 108
Xiong, Y.-Q., Yeaman, M. R., & Bayer, A. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1111 · Cited by 107
The Role of Hydrophobic Substituents in the Biological Activityof Glycopeptide Antibiotics
Kerns, R. J., Dong, S. D., Fukuzawa, S., Carbeck, J. D., Kohler, J., Silver, L. L., & Kahne, D. E. (2000) · Journal of the American Chemical Society · doi:10.1021/ja0027665 · Cited by 101
Synthesis and antibacterial evaluation of N-alkyl vancomycins.
NAGARAJAN, R., Schabel, A. A., Occolowitz, J. L., COUNTER, F. T., OTT, J. L., & Felty-Duckworth, A. M. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.63 · Cited by 86
Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium
Cooper, M. A., & Williams, D. H. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(00)80008-3 · Cited by 85
Molecular basis of the activity of antibiotics of the vancomycin group
Williams, D. H., & Waltho, J. P. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90765-4 · Cited by 85
Allen, N. E., LeTourneau, D. L., & Hobbs, J. N. (1997) · The Journal of Antibiotics · doi:10.7164/antibiotics.50.677 · Cited by 85
Baizman, E. R., Branstrom, A. A., Longley, C. B., Allanson, N. M., Sofia, M. J., Gange, D. M., & Goldman, R. C. (2000) · Microbiology · doi:10.1099/00221287-146-12-3129 · Cited by 81
Studies on the Mode of Action of Reutericyclin
Gänzle, M. G., & Vogel, R. F. (2003) · Applied and Environmental Microbiology · doi:10.1128/aem.69.2.1305-1307.2003 · Cited by 80
Allen, N. E., LeTourneau, D. L., & Hobbs, J. N. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.66 · Cited by 76
Semi-synthetic glycopeptide antibacterials
Judice, J. K., & Pace, J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.067 · Cited by 68
Kohlrausch, U. (1991) · FEMS Microbiology Letters · doi:10.1016/0378-1097(91)90166-8 · Cited by 67
Kohlrausch, U., & Höltje, J.-V. (1991) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1991.tb04451.x · Cited by 63
Allen, N. E., Hobbs, J. N., & Nicas, T. I. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2356 · Cited by 59
Roy, R. S., Ouyang, C., Kodali, S., Xiong, Y., Kim, R. M., Griffin, P. R., Onishi, H. R., Kohler, J., Silver, L. L., & Chapman, K. T. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00075-8 · Cited by 48
Nicas, T. I., MULLEN, D. L., Flokowitsch, J. E., et al. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2585 · Cited by 45
Stratton, C. W., Liu, C., Ratner, H. B., & Weeks, L. S. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1014 · Cited by 44
Nieto, M., Perkins, H. R., & Reynolds, P. E. (1972) · Biochemical Journal · doi:10.1042/bj1260139 · Cited by 37
Hexapeptide Derivatives of Glycopeptide Antibiotics: Tools for Mechanism of Action Studies
Allen, N. E., LeTourneau, D. L., Hobbs, J. N., & Thompson, R. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2344-2348.2002 · Cited by 30
Vollmerhaus, P. J., Breukink, E. J., & Heck, A. J. R. (2003) · Chemistry - A European Journal · doi:10.1002/chem.200390179 · Cited by 25
Cited by
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Lipid II as a target for antibiotics
Breukink, E., & de Kruijff, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2004 · Cited by 701
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600350 · Cited by 672
Development and Challenges of Antimicrobial Peptides for Therapeutic Applications
Chen, C. H., & Lu, T. K. (2020) · Antibiotics · doi:10.3390/antibiotics9010024 · Cited by 598
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Metadata
- Authors
- Higgins, D. L., Chang, R., Debabov, D. V., Leung, J., Wu, T., Krause, K. M., Sandvik, E., Hubbard, J. M., Kaniga, K., Schmidt, D. E., Gao, Q., Cass, R. T., Karr, D. E., Benton, B. M., & Humphrey, P. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2005-03
- Volume
- 49
- Issue
- 3
- Pages
- 1127-1134
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2147723850
- Cited by
- 425
- References
- 49
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.